On the contrary, low expression of ERBB4 protein or mRNA levels have been correlated with shorter overall survival or poor prognosis in hepatocellular carcinoma [22], breast cancer [23], and triple-negative and Her2 positive breast cancer [24]. This evidence concerns the gene ERBB4 and breast cancer.